Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer.

Front Oncol · 2020 · PMC7318110 · PMID 32637350

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the ovarian bursa model ( Figures 4A,B ), the treatment with NEO-201 or NEO-201 in combination with PBMCs, showed a trend toward tumor control.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.